Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 8 for:    sarilumab | Corona Virus Infection

Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (TOCIVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04322773
Recruitment Status : Recruiting
First Posted : March 26, 2020
Last Update Posted : April 7, 2020
Sponsor:
Collaborator:
Lars Erik Kristensen
Information provided by (Responsible Party):
Marius Henriksen, Frederiksberg University Hospital

Brief Summary:

Coronavirus disease 2019 (COVID-19) is caused by the newly discovered coronavirus, SARS-CoV-2. The median time from onset of symptoms of COVID-19 to development of acute respiratory distress syndrome (ARDS) has been reported as short as 9 days. No effective prophylactic or post-exposure therapy is currently available. According to data from the Danish Health Authority (www.sst.dk/corona), as of March 21st, 2020, there were 1326 patients infected with the disease in Denmark, more than 250 are admitted to a hospital, and >50 of them have required intensive care. Nearly 350.000 cases and 15.000 deaths have been reported globally. These numbers are likely to markedly increase during the coming weeks, challenging the capacity of health systems worldwide.

In patients infected with SARS-CoV-2, it has been described that disease severity and outcomes are related to the characteristics of the immune response. Interleukin (IL)-6 and other components of the inflammatory cascade contribute to host defense against infections. However, exaggerated synthesis of IL-6 can lead to an acute severe systemic inflammatory response known as 'cytokine storm'. In the pathogenesis of SARS-CoV-2 pneumonia, a study found that a cytokine storm involving a considerable release of proinflammatory cytokines occurred, including IL-6, IL-12, and tumor necrosis factor α (TNF-α). Studies on the Middle East respiratory syndrome caused by another coronavirus (MERS-CoV), indicate that cytokine genes of IL-6, IL-1β, and IL-8 can be markedly upregulated. Similarly, patients with SARS-CoV-2 pneumonia admitted to an intensive care unit had higher plasma levels of cytokines including IL-6, IL-2, IL-7, IL-10, granulocyte-colony stimulating factor (G-CSF), interferon-γ-inducible protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory protein 1 alpha (MIP1A), and TNF-α. These findings indicate that the magnitude and characteristics of the cytokine response is related to the severity and prognosis of patients with SARS-CoV-2 pneumonia.

It has been suggested that IL-6 blockade may constitute a novel therapeutic strategy for other types of cytokine storm, such as the systemic inflammatory response syndrome including sepsis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Remarkable beneficial effects of IL-6 blockade therapy using a IL-6 receptor inhibitor has been described in patients with severe SARS-CoV-2 pneumonia in a retrospective case series from China.

Currently, there are two available drugs based on human monoclonal antibodies against IL-6 receptor, tocilizumab (RoActemra, Roche) and sarilumab (Kevzara, Sanofi). IL-6 receptor inhibitors are currently licensed for several autoimmune disorders and are considered well tolerated and safe in general. The most common side effects reported are upper respiratory tract infections, headache, hypertension, and abnormal liver function tests. The most serious side effects are serious infections, complications of diverticulitis, and hypersensitivity reactions.

it is hypothesized that IL-6 might play a key role in the cytokine storm associated with serious adverse outcomes in patients infected with SARS-CoV-2 pneumonia, and that blockade of IL-6 would be suitable therapeutic target for these patients. The study will investigate the effect of different types of IL-6 inhibition versus no adjuvant treatment compared to standard of care in patients with severe SARS-CoV-2 pneumonia.

Primary objective: To compare the effect of either one of three IL-6 inhibitor administrations, relative to the standard of care, on time to independence from supplementary oxygen therapy, measured in days from baseline to day 28, in patients with severe SARS-CoV-2 pneumonia.


Condition or disease Intervention/treatment Phase
Corona Virus Disease Drug: RoActemra iv Drug: RoActemra sc Drug: Kevzara sc Other: Standard medical care Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial
Actual Study Start Date : April 5, 2020
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : June 1, 2021

Arm Intervention/treatment
Experimental: Roactemra iv
Single dose treatment with 400 mg tocilizumab intravensously
Drug: RoActemra iv
single dose treatment with tocilizumab 400 mg intravenously
Other Name: tocilizumab 400 mg

Other: Standard medical care
management as usual

Experimental: Roactemra sc
Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
Drug: RoActemra sc
single dose treatment with tocilizumab 2 x 162 mg subcutaneously
Other Name: tocilizumab 2 x 162 mg

Other: Standard medical care
management as usual

Experimental: Kevzara sc
Single dose treatment with 1 x 200 mg sarilumab subcutaneously
Drug: Kevzara sc
single dose treatment with sarilumab 1 x 200 mg subcutaneously
Other Name: sarilumab 1 x 200 mg

Other: Standard medical care
management as usual

Active Comparator: Standard care
Management as usual
Other: Standard medical care
management as usual




Primary Outcome Measures :
  1. Time to independence from supplementary oxygen therapy [ Time Frame: days from enrolment up 28 days ]

Secondary Outcome Measures :
  1. Number of deaths [ Time Frame: 28 days from enrolment ]
  2. Days out of hospital and alive [ Time Frame: 28 days from enrolment ]
  3. Ventilator free days alive and out of hospital [ Time Frame: 28 days from enrolment ]
  4. C-reactive protein (CRP) level [ Time Frame: baseline ]
    Measured from standard blood test

  5. C-reactive protein (CRP) level [ Time Frame: peak during hospitalisation, up to 28 days ]
    Measured from standard blood test

  6. C-reactive protein (CRP) level [ Time Frame: 14 days ]
    Measured from standard blood test

  7. C-reactive protein (CRP) level [ Time Frame: 28 days ]
    Measured from standard blood test

  8. Number of participants with serious adverse events [ Time Frame: During treatment, up to 28 days ]
    Measured as occurrence of any serious adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • SARS-CoV-2 infection confirmed by real time-PCR and
  • Positive imaging: consolidation, ground glass opacities, or bilateral pulmonary infiltration either by CT-scan or chest x-ray; and
  • Need of oxygen therapy to maintain SO2>94% OR FiO2/PaO2 > 20 and at least two of the following laboratory measures:
  • CRP level >70 mg/L
  • CRP level >= 40 mg/L and doubled within 48 hours (without other confirmed infectious or non-infectious course),
  • Lactatdehydrogenase > 250 U/L,
  • thrombocytopenia < 120.000 x 10E9/L,
  • lymphocyte count < 0.6 x 10E9/L,
  • D-dimer > 1 ug/mL,
  • serum ferritin > 300 ug/mL

Exclusion Criteria:

  • pregnancy suspected or confirmed,
  • severe heart failure,
  • suspected or confirmed bacterial infection,
  • current solid or hematological malignancy,
  • neutropenia,
  • ALAT elevation more than three times the laboratory upper limit,
  • ASA class 5 (after COVID19 admission) or higher at inclusion (prior admission),
  • severe chronic obstructive pulmonary disease or heart failure (NYHA class II or higher),
  • pregnant or lactating women,
  • current treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs)/immunosuppressive agents including IL-6 inhibitors, or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period,
  • current use of chronic oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day,
  • previous or active tuberculosis (TB),
  • HIV infection regardless of immunological status, hepatitis,
  • evidence of recent (30 days) invasive bacterial or fungal infections,
  • patients who have received immunosuppressive antibody therapy within the past 5 months, including intravenous immunoglobulin or plans to receive during the study period,
  • IV drug abuse,
  • history of inflammatory bowel disease,
  • diverticulitis,
  • ulcer,
  • perforated gastrointestinal tract,
  • participation in any clinical research study evaluating an investigational product (IP) or therapy within 3 months and less than five half-lives of IP prior inclusion to the study,
  • any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study,
  • inability to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04322773


Contacts
Layout table for location contacts
Contact: Lars Erik Kristensen, PhD 0045 38164157 lars.erik.kristensen@regionh.dk

Locations
Layout table for location information
Denmark
Bispebjerg-Frederiksberg Hospital Recruiting
Copenhagen, Denmark, 2000
Contact: Lars Erik Kristensen, PhD    0045 38164157    lars.erik.kristensen@regionh.dk   
Contact: Line Rustad    0045 38164158    line.rustad@regionh.dk   
Principal Investigator: Lars Erik Kristensen, PhD         
Hillerød Hospital Recruiting
Hillerød, Denmark
Contact: Zitta harboe         
Sponsors and Collaborators
Marius Henriksen
Lars Erik Kristensen
Investigators
Layout table for investigator information
Principal Investigator: Lars Erik Kristensen, PhD The Parker Institute
Layout table for additonal information
Responsible Party: Marius Henriksen, Professor, Frederiksberg University Hospital
ClinicalTrials.gov Identifier: NCT04322773    
Other Study ID Numbers: APPI2-CV-2020-01
First Posted: March 26, 2020    Key Record Dates
Last Update Posted: April 7, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases